Fusion Pharm (FSPM) Stock Price

Fusion Pharm Price

OTC·CLOSED
0.00USD+0.00 (+0.00 %)
Market closed

Revenue at Fusion Pharm has contracted by 12.1% per year over the past 18 years to 808,400.00 USD. Fusion Pharm's net margin stands at 32.8%, up from -28.5% several years earlier.

Fusion Pharm stock price

Volume
Details

Stock Price

ⓘ

How to Read This Chart

This chart tracks the historical stock price of Fusion Pharm over time. You can switch between daily, weekly, and monthly views and select custom time ranges — from a single day to the full available history. Use the toggle to view price changes in absolute currency terms or as a percentage change relative to the starting date.

Total Return vs. Price Return

The "Total Return" toggle includes reinvested dividends on top of the pure price movement. This is critical because dividends can account for a significant portion of long-term returns. Historically, roughly 40 % of the S&P 500's total return has come from dividends. Always compare total return when evaluating a stock's real performance against a benchmark.

Intraday Price Data

When viewing a one-day time frame, the chart displays real-time intraday price movements. This is useful for observing how Fusion Pharm stock reacts to market openings, earnings releases, or breaking news throughout the trading session.

What to Look For

Look for long-term trends (sustained upward or downward movements over months and years), support and resistance levels (price zones where the stock repeatedly bounces or reverses), and volatility (how much the price fluctuates day to day). Comparing Fusion Pharm's price chart to a market index like the S&P 500 can reveal whether the stock is outperforming or underperforming the broader market.

Fusion Pharm Stock Price History
DateFusion Pharm Price
8/20/20260.00 USD
8/19/20260.00 USD
8/18/20260.00 USD
8/17/20260.00 USD
8/14/20260.00 USD
8/13/20260.00 USD
8/12/20260.00 USD
8/11/20260.00 USD
8/10/20260.00 USD
8/7/20260.00 USD
8/6/20260.00 USD
8/5/20260.00 USD
8/4/20260.00 USD
8/3/20260.00 USD
7/30/20260.00 USD
7/29/20260.00 USD
7/28/20260.00 USD
7/27/20260.00 USD
7/24/20260.00 USD
7/23/20260.00 USD
7/22/20260.00 USD
7/21/20260.00 USD
7/20/20260.00 USD
7/17/20260.00 USD
7/16/20260.00 USD
7/15/20260.00 USD
7/14/20260.00 USD
7/13/20260.00 USD
7/10/20260.00 USD
7/9/20260.00 USD
7/8/20260.00 USD
7/7/20260.00 USD
7/6/20260.00 USD
7/3/20260.00 USD
7/2/20260.00 USD
7/1/20260.00 USD
6/30/20260.00 USD
6/29/20260.00 USD
6/26/20260.00 USD
6/25/20260.00 USD
6/24/20260.00 USD
6/23/20260.00 USD
6/22/20260.00 USD
6/19/20260.00 USD
6/18/20260.00 USD
6/17/20260.00 USD
6/16/20260.00 USD
6/15/20260.00 USD
6/12/20260.00 USD
6/11/20260.00 USD
6/10/20260.00 USD
6/9/20260.00 USD
6/8/20260.00 USD
6/5/20260.00 USD
6/4/20260.00 USD
6/3/20260.00 USD
6/2/20260.00 USD
6/1/20260.00 USD
5/29/20260.00 USD
5/28/20260.00 USD
5/27/20260.00 USD
5/26/20260.00 USD
5/25/20260.00 USD
5/22/20260.00 USD
5/21/20260.00 USD
5/20/20260.00 USD
5/19/20260.00 USD
5/18/20260.00 USD
5/15/20260.00 USD
5/14/20260.00 USD
5/13/20260.00 USD
5/12/20260.00 USD
5/11/20260.00 USD
5/8/20260.00 USD
5/7/20260.00 USD
5/6/20260.00 USD
5/5/20260.00 USD
5/4/20260.00 USD
5/1/20260.00 USD
4/30/20260.00 USD
4/29/20260.00 USD
4/28/20260.00 USD
4/27/20260.00 USD
4/24/20260.00 USD
4/23/20260.00 USD
4/22/20260.00 USD
4/21/20260.00 USD
4/20/20260.00 USD
4/17/20260.00 USD
4/16/20260.00 USD
4/15/20260.00 USD
4/14/20260.00 USD
4/13/20260.00 USD
4/10/20260.00 USD
4/9/20260.00 USD
4/8/20260.00 USD
4/7/20260.00 USD
4/6/20260.00 USD
4/2/20260.00 USD
4/1/20260.00 USD
3/31/20260.00 USD
3/30/20260.00 USD
3/27/20260.00 USD
3/26/20260.00 USD
3/25/20260.00 USD
3/24/20260.00 USD
3/23/20260.00 USD
3/20/20260.00 USD
3/19/20260.00 USD
3/18/20260.00 USD
3/17/20260.00 USD
3/16/20260.00 USD
3/13/20260.00 USD
3/12/20260.00 USD
3/11/20260.00 USD
3/10/20260.00 USD
3/9/20260.00 USD
3/6/20260.00 USD
3/5/20260.00 USD
3/4/20260.00 USD
3/3/20260.00 USD
3/2/20260.00 USD
2/27/20260.00 USD
2/26/20260.00 USD
2/25/20260.00 USD
2/24/20260.00 USD
2/23/20260.00 USD
2/20/20260.00 USD
2/19/20260.00 USD
2/18/20260.00 USD
2/17/20260.00 USD
2/13/20260.00 USD
2/12/20260.00 USD
2/11/20260.00 USD
2/10/20260.00 USD
2/9/20260.00 USD
2/6/20260.00 USD
2/5/20260.00 USD
2/4/20260.00 USD
2/3/20260.00 USD
2/2/20260.00 USD
1/30/20260.00 USD
1/29/20260.00 USD
1/28/20260.00 USD
1/27/20260.00 USD
1/26/20260.00 USD
1/23/20260.00 USD
1/22/20260.00 USD
1/21/20260.00 USD
1/20/20260.00 USD
1/16/20260.00 USD
1/15/20260.00 USD
1/14/20260.00 USD
1/13/20260.00 USD
1/12/20260.00 USD
1/9/20260.00 USD
1/8/20260.00 USD
1/7/20260.00 USD
1/6/20260.00 USD
1/5/20260.00 USD
1/2/20260.00 USD
12/31/20250.00 USD
12/30/20250.00 USD
12/29/20250.00 USD
12/26/20250.00 USD
12/24/20250.00 USD
12/23/20250.00 USD
12/22/20250.00 USD
12/19/20250.00 USD
12/18/20250.00 USD
12/17/20250.00 USD
12/16/20250.00 USD
12/15/20250.00 USD
12/12/20250.00 USD
12/11/20250.00 USD
12/10/20250.00 USD
12/9/20250.00 USD
12/8/20250.00 USD
12/5/20250.00 USD
12/4/20250.00 USD
12/3/20250.00 USD
12/2/20250.00 USD
12/1/20250.00 USD
11/28/20250.00 USD
11/26/20250.00 USD
11/25/20250.00 USD
11/24/20250.00 USD
11/21/20250.00 USD
11/20/20250.00 USD
11/19/20250.00 USD
11/18/20250.00 USD
11/17/20250.00 USD
11/14/20250.00 USD
11/13/20250.00 USD
11/12/20250.00 USD
11/11/20250.00 USD
11/10/20250.00 USD
11/7/20250.00 USD
11/6/20250.00 USD
11/5/20250.00 USD
11/4/20250.00 USD
11/3/20250.00 USD
10/31/20250.00 USD
10/30/20250.00 USD
10/29/20250.00 USD
10/28/20250.00 USD
10/27/20250.00 USD
10/24/20250.00 USD
10/23/20250.00 USD
10/22/20250.00 USD
10/21/20250.00 USD
10/20/20250.00 USD
10/17/20250.00 USD
10/16/20250.00 USD
10/15/20250.00 USD
10/14/20250.00 USD
10/13/20250.00 USD
10/10/20250.00 USD
10/9/20250.00 USD
10/8/20250.00 USD
10/7/20250.00 USD
10/6/20250.00 USD
10/3/20250.00 USD
10/2/20250.00 USD
10/1/20250.00 USD
9/30/20250.00 USD
9/29/20250.00 USD
9/26/20250.00 USD
9/25/20250.00 USD
9/24/20250.00 USD
9/23/20250.00 USD
9/22/20250.00 USD
9/19/20250.00 USD
9/18/20250.00 USD
9/17/20250.00 USD
9/16/20250.00 USD
9/15/20250.00 USD
9/12/20250.00 USD
9/11/20250.00 USD
9/10/20250.00 USD
9/9/20250.00 USD
9/8/20250.00 USD
9/5/20250.00 USD
9/4/20250.00 USD
9/3/20250.00 USD
9/2/20250.00 USD
8/29/20250.00 USD
8/28/20250.00 USD
8/27/20250.00 USD
8/26/20250.00 USD
8/25/20250.00 USD
Access this data via the Eulerpool API
Get Free API Key

Fusion Pharm Revenue, EBIT, Net Income

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details
Date
Revenue
EBIT
Net Income
Jan 1, 1994
8.28 M USD
-982,000.00 USD
-1.16 M USD
Jan 1, 1995
7.99 M USD
-2.52 M USD
-2.28 M USD
Jan 1, 1996
883,000.00 USD
-2.25 M USD
-883,000.00 USD
Jan 1, 1997
30,000.00 USD
-304,000.00 USD
-406,000.00 USD
Jan 1, 2011
227,400.00 USD
-327,600.00 USD
-402,400.00 USD
Jan 1, 2012
808,400.00 USD
298,400.00 USD
265,200.00 USD

Fusion Pharm Income Statement, Balance Sheet, Cash Flow Statement

Last updated Aug 24, 2026, 6:06 AM
 
REVENUEM USD
REVENUE GROWTH%
GROSS MARGIN%
GROSS INCOMEM USD
EBITM USD
EBIT MARGIN%
NET INCOMEM USD
NET INCOME GROWTH%
SHARESM
199419951996199720112012
8.007.00––––
–-12.50––––
-25.00-14.29––––
-2.00-1.00-2.00-2.00-2.00-2.00
–-2.00-2.00–––
–-28.57––––
-1.00-2.00––––
–100.00––––
0.100.130.130.102.122.55
Details

Income Statement Key Figures

ⓘ

Revenue and Revenue Growth

Revenue is the starting point of every income statement — it measures the total sales Fusion Pharm generates from its core business. Revenue growth (expressed as year-over-year percentage change) is one of the most important indicators of business momentum. Sustained growth above 10 % annually is generally considered strong, while declining revenue is a serious warning sign that demands investigation.

Gross Margin

Gross margin = (Revenue − Cost of Goods Sold) ÷ Revenue. It reveals what percentage of each dollar of revenue Fusion Pharm retains after direct production costs. High gross margins (above 50 %) are typical of asset-light businesses like software and brands, while capital-intensive industries like manufacturing often operate below 30 %. Compare Fusion Pharm's gross margin to industry peers and track it over time to spot improving or deteriorating pricing power.

EBIT and EBIT Margin

EBIT measures operating profit — what remains after subtracting all operating expenses (including R&D, sales, and administrative costs) from gross profit. The EBIT margin shows this as a percentage of revenue. Because it excludes interest and taxes, EBIT allows fair comparisons between companies with different debt levels and tax jurisdictions. A rising EBIT margin indicates improving operational efficiency.

Net Income and Earnings Per Share (EPS)

Net income is the company's final profit after all expenses, interest, and taxes. Dividing net income by the number of shares outstanding gives you EPS — the single most influential metric in stock valuation. Consistent EPS growth is the primary driver of long-term stock price appreciation. Always check whether EPS growth comes from genuine profit improvement or from share buybacks reducing the share count.

Shares Outstanding

The total number of shares Fusion Pharm has issued. A declining share count (through buybacks) boosts EPS and signals management confidence. A rising share count (through stock issuance) dilutes existing shareholders. Always monitor this number alongside EPS to get the full picture of per-share value creation.

Analyst Estimates

The projected figures represent consensus estimates from professional analysts. Compare these forecasts against Fusion Pharm's historical growth rates to assess whether expectations are realistic. A company that consistently beats consensus estimates tends to see its stock price rewarded over time, while repeated misses erode investor confidence.

Fusion Pharm stock margins

The Fusion Pharm margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Fusion Pharm. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Fusion Pharm.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details
Date
Gross margin
EBIT margin
Profit margin
Jan 1, 1994
-2.86 %
-11.87 %
-14.03 %
Jan 1, 1995
-13.73 %
-31.56 %
-28.50 %
Jan 1, 1996
-236.92 %
-255.27 %
-100.00 %
Jan 1, 1997
-680.00 %
-1,013.33 %
-1,353.33 %
Jan 1, 2011
30.56 %
-144.06 %
-176.96 %
Jan 1, 2012
83.67 %
36.91 %
32.81 %

Fusion Pharm Stock Revenue, EBIT, Earnings per Share

The Fusion Pharm earnings per share therefore indicates how much revenue Fusion Pharm has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue per Share
EBIT per share
Earnings per Share
Details
Date
Revenue per Share
EBIT per share
Earnings per Share
Jan 1, 1994
81.78 USD
-9.70 USD
-11.47 USD
Jan 1, 1995
60.95 USD
-19.24 USD
-17.37 USD
Jan 1, 1996
6.83 USD
-17.43 USD
-6.83 USD
Jan 1, 1997
0.31 USD
-3.17 USD
-4.24 USD
Jan 1, 2011
0.11 USD
-0.15 USD
-0.19 USD
Jan 1, 2012
0.32 USD
0.12 USD
0.10 USD

Fusion Pharm business model & stock analysis

Fusion Pharm Inc is a well-known company in the agricultural industry that operates in various business sectors. It was founded in 2010 by Scott Dittman with the idea of improving agricultural efficiency through the use of innovative technologies. Fusion Pharm has gradually built different business areas focused on the development and marketing of products for optimizing agriculture. One of Fusion Pharm's core areas is the production of modular cultivation systems for plants that utilize cutting-edge technologies. These systems, called "PharmaCubes," are designed to provide optimal conditions for plants and achieve higher crop yields. They are particularly intended for use in urban spaces and other environments where traditional cultivation methods may not be feasible. The advantage of these systems lies in their scalability, and they are optimized for indoor use. Another important business area for Fusion Pharm is the production of fertilizers and other agricultural chemicals. These products are marketed under the brand name "Agritabs" and are aimed at promoting healthier plant growth and higher crop yields. The agricultural chemicals are made from natural raw materials, making them more environmentally friendly than many other products on the market. They are intended for use in various industries, including agriculture, gardening and landscaping, and the food industry. In addition to manufacturing and supplying cultivation systems, Fusion Pharm also operates in the production and distribution of natural fertilizers and other agricultural chemicals. The company has also undertaken a pilot project for closed-room fish farming and established itself in the aquaculture industry. In recent years, the company has pursued an aggressive acquisition strategy to expand into new business fields. One of these acquisitions was the takeover of the cloud-based software company "CannaCube," which has developed a management system for cannabis cultivation. Through the acquisition of CannaCube, Fusion Pharm has now positioned its portfolio for the growing cannabis industry. The company has made a name for itself in the agricultural industry by optimizing existing processes for sustainable and efficient plant development. With its innovative technology and products, the company contributes to greater efficiency and a more environmentally friendly agricultural industry.

Fusion Pharm SWOT Analysis

Strengths

Fusion Pharm Inc has several strengths that contribute to its success. One of the key strengths is its advanced technology and expertise in the pharmaceutical industry. The company has a strong portfolio of patented products and innovative solutions, allowing it to stay ahead of its competitors.

Additionally, Fusion Pharm Inc has a robust distribution network, enabling efficient and widespread access to its products. The company also benefits from a strong customer base and loyal partnerships, which further enhances its market presence and revenue generation.

Weaknesses

Despite its strengths, Fusion Pharm Inc also has some weaknesses that may hinder its growth. One major weakness is the company's limited financial resources. This restricts its ability to invest in research and development, expansion plans, and marketing initiatives.

Furthermore, the company heavily relies on a few key suppliers, making it vulnerable to supply chain disruptions and fluctuations in raw material prices. In addition, Fusion Pharm Inc may face challenges in maintaining regulatory compliance, especially in a highly regulated industry like pharmaceuticals.

Opportunities

Fusion Pharm Inc can leverage several opportunities to further its growth and profitability. One significant opportunity is the increasing global demand for pharmaceutical products. The company can explore new markets and expand its customer base, both domestically and internationally.

Additionally, the rising focus on research and development in the healthcare sector provides an opportunity for Fusion Pharm Inc to develop and introduce innovative products and solutions. Furthermore, strategic partnerships and collaborations with other industry players can open doors to new opportunities and synergies.

Threats

Fusion Pharm Inc faces various threats that could impact its performance. One major threat is intense competition within the pharmaceutical industry. The company needs to continuously innovate and differentiate itself to stay ahead in the market and retain its customer base.

Moreover, changes in government regulations and policies, especially related to healthcare and drug approvals, pose a threat to Fusion Pharm Inc. The company must stay updated and compliant with these regulations to avoid legal and operational challenges.

Additionally, economic uncertainties and fluctuations in currency exchange rates can impact the company's financial stability, as well as the pricing of its products in different markets.

Fusion Pharm Eulerpool Fair Value

Details

Fair Value Estimate

ⓘ

What Is Fair Value?

Fair value is an estimate of what a stock is truly "worth" based on its financial fundamentals, independent of the current market price. If the calculated fair value is above the current share price, the stock may be undervalued — and vice versa. This chart shows three different fair value approaches so you can cross-check them against each other.

Earnings-Based Fair Value

Calculated by multiplying the current earnings per share (EPS) by the average historical P/E ratio over a selected multi-year period. The smoothing over several years filters out temporary spikes or dips. If this fair value exceeds the market price, it suggests the stock is cheap relative to its earning power.

Example: Fair Value (Earnings) 2022 = EPS 2022 × Average P/E 2019–2021

Revenue-Based Fair Value

Derived by multiplying revenue per share by the average historical price-to-sales ratio. This method is particularly useful for companies with volatile or temporarily depressed earnings, as revenue tends to be more stable than profits. It answers: "At what price has the market historically valued each dollar of this company's sales?"

Example: Fair Value (Revenue) 2022 = Revenue per Share 2022 × Average P/S 2019–2021

Dividend-Based Fair Value

Calculated by dividing the dividend per share by the average historical dividend yield. This approach is most relevant for mature, consistently dividend-paying companies. If the resulting fair value is higher than the current price, it implies the stock offers a better yield than its historical average.

Example: Fair Value (Dividend) 2022 = Dividend per Share 2022 ÷ Average Yield 2019–2021

How to Use This Chart

When all three fair value lines converge above the current price, it strengthens the case that the stock is undervalued. When they diverge, investigate why — it may indicate a structural shift in margins, payout policy, or growth rate. The forward estimates on the right extend the analysis using projected fundamentals, helping you assess whether the current price already reflects future growth expectations.

Fusion Pharm historical P/E ratio, EBIT multiple, and P/S ratio

Fusion Pharm annual returns

Details

Annual Return

ⓘ

What This Chart Shows

This chart breaks down 's total annual return into two components: price return (gains or losses from stock price movement) and dividend return (income received from dividend payments). Together, they represent the total return an investor would have earned in each calendar year.

Price Return

Price return measures the percentage change in 's stock price from January 1st to December 31st of each year. Positive bars indicate the stock appreciated; negative bars show a decline. This is the component most investors focus on, but it tells only part of the story — especially for dividend-paying stocks.

Dividend Return

Dividend return represents the income generated from dividends paid during the year, expressed as a percentage of the starting stock price. While it may seem small in any single year (typically 1–4 % for established companies), dividends compound significantly over decades and have historically contributed roughly 40 % of total stock market returns.

What to Look For

Examine how many years showed positive vs. negative returns to gauge consistency. A stock with mostly positive years and small drawdowns suggests lower risk. Also compare 's annual returns to a benchmark index — consistently outperforming the market is a hallmark of a strong investment. Pay attention to the worst years: understanding downside risk is just as important as chasing upside potential.

Fusion Pharm shares outstanding

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Number of stocks
Details
Date
Number of stocks
Jan 1, 1994
101,200.00 Stocks
Jan 1, 1995
131,100.00 Stocks
Jan 1, 1996
129,300.00 Stocks
Jan 1, 1997
95,800.00 Stocks
Jan 1, 2011
2.12 M Stocks
Jan 1, 2012
2.55 M Stocks

Fusion Pharm stock splits

In Fusion Pharm's history, there have been no stock splits.
Price targets and forecasts for Fusion Pharm are not yet available.

Fusion Pharm shareholder structure

% Name
0.07830%
ORG Partners LLC
ORG Partners LLC

Frequently asked questions about Fusion Pharm

The business model of Fusion Pharm Inc is centered around providing innovative vertical farming solutions. The company designs and manufactures state-of-the-art cultivation systems known as PharmPods, which are fully equipped shipping containers for growing produce in a controlled environment. Fusion Pharm's business model aims to revolutionize the agriculture industry by offering efficient and sustainable farming solutions that optimize space, resources, and yields. With its cutting-edge technology and expertise in vertical farming, Fusion Pharm Inc aims to meet the increasing demand for locally grown, pesticide-free, and high-quality food products.

Fusion Pharm Inc is primarily active in the industries of horticulture, agriculture, and cannabis cultivation.

The main competitors of Fusion Pharm Inc in the market include companies like GrowLife Inc, Terra Tech Corp, and MedMen Enterprises Inc.

Fusion Pharm Inc, now known as Pharmagreen Biotech Inc, is a Canadian cannabis company. Founded in 2011, Fusion Pharm initially focused on providing vertical farming solutions for growing medicinal herbs and leafy greens. However, in 2018, the company shifted its focus to the cannabis industry and rebranded as Pharmagreen Biotech. With a mission to revolutionize the cannabis cultivation industry, Pharmagreen specializes in the development and licensing of tissue culture plantlets. Through their proprietary technology, the company aims to produce genetically superior, disease-free plantlets while reducing cultivation costs and enhancing overall yields. Pharmagreen Biotech Inc continues to innovate and contribute to the advancement of the cannabis sector.

Fusion Pharm Inc has achieved several significant milestones. The company successfully developed and patented its proprietary PharmPods™ technology, which revolutionizes the cultivation of organic produce and medicinal plants. Fusion Pharm Inc also established strategic partnerships with leading horticultural and agricultural companies, enabling widespread adoption of their innovative growing systems. Additionally, the company expanded its operations internationally, reaching markets in Europe, Asia, and the Americas. Fusion Pharm Inc's dedication to sustainable and efficient cultivation methods has garnered accolades and recognition within the industry. These achievements highlight Fusion Pharm Inc's commitment to advancing the field of indoor agriculture.

Fusion Pharm Inc is primarily present in the United States.

Fusion Pharm Inc represents values of innovation, sustainability, and growth in the agricultural industry. With a focus on providing cutting-edge vertical farming technologies, the company aims to revolutionize traditional farming practices. Fusion Pharm Inc believes in the importance of environmentally friendly solutions that maximize crop production while minimizing resource usage. By fostering partnerships and collaborations, Fusion Pharm Inc strives to create a global network of sustainable farming systems. With a commitment to advancing the future of agriculture, Fusion Pharm Inc is dedicated to providing efficient and profitable solutions for farmers around the world.

Converted at the current exchange rate, the Fusion Pharm share trades at 0.00 EUR (0.00 USD).

Fusion Pharm Inc is a company that operates in various business areas, including the manufacturing of greenhouses, production of primarily organic supplements, and offering consulting services for agriculture and construction.

The revenue cannot currently be calculated for Fusion Pharm.

The profit cannot currently be calculated for Fusion Pharm.

The P/E ratio cannot be calculated for Fusion Pharm at the moment.

The P/S cannot be calculated for Fusion Pharm currently.

The Eulerpool Quality Score for Fusion Pharm is 3/10.

The ISIN of Fusion Pharm is US36113H1005. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.

The WKN of Fusion Pharm is A1H9CD. The WKN (Wertpapierkennnummer) is a six-digit German security identification number.

The ticker of Fusion Pharm is FSPM. The ticker symbol is used to trade Fusion Pharm shares on the stock exchange.

Fusion Pharm paid dividends every year for the past 0 years.

Fusion Pharm is assigned to the 'Non-cyclical consumption' sector.

The dividends of Fusion Pharm are distributed in USD.

All fundamentals and in-depth analysis of Fusion Pharm

Our stock analysis for Fusion Pharm stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Fusion Pharm. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.

Fusion Pharm Stock
Fusion Pharm Revenue→
Fusion Pharm Stock
Fusion Pharm Net Income→
Fusion Pharm Stock
Fusion Pharm P/E→
Fusion Pharm Stock
Fusion Pharm P/S→
Fusion Pharm Stock
Fusion Pharm EBIT→
Fusion Pharm Stock
Fusion Pharm Dividend→
Fusion Pharm Stock
Fusion Pharm Directors Dealings→
Fusion Pharm Stock
Fusion Pharm Stocks→
Fusion Pharm Stock
Fusion Pharm Market capitalization→
Fusion Pharm Stock
Fusion Pharm Debt→
Fusion Pharm Stock
Fusion Pharm Liabilities→
Fusion Pharm Stock
Fusion Pharm Equity→
Fusion Pharm Stock
Fusion Pharm AAQS→
Fusion Pharm Stock
Fusion Pharm Employees→
Fusion Pharm Stock
Fusion Pharm ROE→
Fusion Pharm Stock
Fusion Pharm ROA→
Fusion Pharm Stock
Fusion Pharm ROCE→
Fusion Pharm Stock
Fusion Pharm News→
Fusion Pharm Stock
Fusion Pharm Analyst Price Targets→

Non-cyclical consumption Stocks

Fuss BrandsFuse ScienceFuture ConsumerFUNRFuture RetailFull Motion BeverageFwusow Industry CoFukutome Meat PackersFyolo TechnologyFujiya CoG M BreweriesFujing Holdings CoAll Stocks A–Z →